Related Experiment Video
Updated: Feb 11, 2026

Generation of Fluorescent Protein Fusions in Candida Species
Published on: March 4, 2017
Emergence of Nonalbicans Candida Species in Immunocompromised Leukemia Patients during Fluconazole Treatment
Kunio Yano1, Shinya Fujisawa1, Hirotaka Matsui1
1Department of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan.
Abstract:
The incidence of the emergence of nonalbicans Candida species during fluconazole treatment was surveyed in leukemia patients who were severely immunocompromised due to either intensive chemotherapy or bone marrow transplantation during the 3-year period from April 1993 to March 1996. Thirty-three patients received either prophylactic or therapeutic fluconazole administration for at least 7 days. In 7 of these 33 patients (21.2%), nonalbicans Candida including C. krusei, C. glabrata, C. maris, and C. inconspicua emerged during, or immediately after, fluconazole administration, with C. inconspicua the most prevalent Candida spp. Since these yeast strains are resistant to fluconazole, it is possible that selection occurred favoring Candida spp. resistant to fluconazole. Therefore, surveillance for yeast strains resistant to fluconazole should be performed as a routine procedure during fluconazole administration. In cases of resistance, other effective antifungal agents should be administered.
Insights
In severely immunocompromised leukemia patients, non-albicans Candida species resistant to fluconazole emerged in 21.2% of cases. Routine surveillance for fluconazole-resistant yeast is crucial during treatment.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Hematology
Background:
- Patients with leukemia undergoing intensive chemotherapy or bone marrow transplantation are severely immunocompromised.
- Antifungal prophylaxis and treatment are critical in managing invasive fungal infections in these vulnerable populations.
Purpose of the Study:
- To survey the incidence of non-albicans Candida species emergence during fluconazole treatment in leukemia patients.
- To identify specific non-albicans Candida species that emerge and assess their susceptibility to fluconazole.
Main Methods:
- A 3-year prospective study (April 1993-March 1996) involving 33 leukemia patients receiving fluconazole.
- Monitoring for the emergence of non-albicans Candida species during or immediately after fluconazole administration.
Main Results:
- Non-albicans Candida species emerged in 7 out of 33 patients (21.2%).
- Candida inconspicua was the most prevalent emerging species, alongside C. krusei, C. glabrata, and C. maris.
- The emerged yeast strains demonstrated resistance to fluconazole, suggesting selection pressure.
Conclusions:
- Fluconazole treatment can select for resistant non-albicans Candida species in immunocompromised leukemia patients.
- Routine surveillance for fluconazole-resistant yeast strains is recommended during treatment.
- Alternative effective antifungal agents should be administered in cases of resistance.
Related Concept Videos
What is a Species?
Emerging Adulthood
Keystone Species
Formation of Species
Introduction Cardiac Emergencies
Applications of GIS: Disaster Management and Emergency Response

